Stockscreener 앱 받기
94.12
0.94%
0.88
시간 외 거래:
93.81
-0.31
-0.33%
전일 마감가:
$93.24
열려 있는:
$93.86
하루 거래량:
16.41M
Relative Volume:
1.29
시가총액:
$163.94B
수익:
$45.13B
순이익/손실:
$6.28B
주가수익비율:
26.22
EPS:
3.5895
순현금흐름:
$7.38B
1주 성능:
+6.46%
1개월 성능:
+8.60%
6개월 성능:
-24.61%
1년 성능:
-29.59%
1일 변동 폭
$93.21
$95.21
1주일 범위
$87.21
$95.21
52주 변동 폭
$81.97
$137.49
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
94.12 | 163.94B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
332.71 | 127.55B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.98 | 103.66B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.23 | 65.74B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.78 | 52.27B | 6.30B | 1.07B | 1.09B | 1.8406 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-22 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
US DOJ closes criminal probe into Abbott over baby formula plant, WSJ reports - Reuters
In a Volatile Market, This Dividend Growth Stock Is Worth Every Penny of $1,000 - The Motley Fool
Abbott's Dual-Analyte Bet Positions It to Outpace Dexcom in the Expanding CGM Market - Kavout | AI
Abbott Laboratories (ABT) must face a Lawsuit over PediaSure, Statements about Children’s Growth - Insider Monkey
Brain Implants Market Size to Reach USD 18.39 Billion by 2035, Growing at 9.99% CAGR | SNS Insider - GlobeNewswire Inc.
Abbott Laboratories (ABT) Stock After Recent Rebound Is There Still Value Left - Yahoo Finance
Abbott Laboratories' Q2 2026 earnings: What to expect - MSN
Abbott (ABT) Expands In Europe With Instinct CGM And Emerging Market Medicines - simplywall.st
Abbott vs. DexCom: Which CGM Stock Is the Better Option Right Now? - The Globe and Mail
Abbott Laboratories' Q2 2026 Earnings: What to Expect - Barchart.com
Abbott Laboratories sets Q2 earnings date, shares trade firmly on NYSE - Ad-hoc-news.de
Should you buy Abbott Labs stock hand over fist before July 16? - MSN
Abbott shares drop amid sector rotation but growth in diabetes and devices signals buying opportunity. - Pluang
Abbott Laboratories(NYSE: ABT) dropped from Russell Top 50 Index - marketscreener.com
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Abbott Laboratories Stock (ABT) Moved Up by 3.12% on Jun 25: A Full Analysis - TradingKey
Buy, Hold, or Sell: Tech Compression Dragged Abbott Labs Under $91, but 1 Massive Diabetes Catalyst Makes It a Screaming Buy - AOL.com
Abbott Laboratories highlights diagnostics growth, shares sit in the S&P 500 health cohort - Ad-hoc-news.de
Price to sales forward of Abbott Laboratories – LSX:850103 - TradingView
Abbott to post Q2 results July 16, then host live webcast - Stock Titan
How An ALZpath Alzheimer’s Test Deal And Dividend Streak At Abbott (ABT) Has Changed Its Investment Story - simplywall.st
How Does Wall Street View Abbott Laboratories (ABT)’s Outlook? - Insider Monkey
ALZpath and Abbott Partner to Develop New Blood Test for Alzheimer’s Disease - Clinical Lab Products
Got $2,500? 1 Unstoppable Dividend Aristocrat With an Ironclad Moat to Buy - 24/7 Wall St.
Abbott partners with ALZpath on Alzheimer’s blood test - grafa.com
MiniMed Launches Abbott's Instinct Sensors Across European Markets - Yahoo Finance Singapore
ALZpath signs licensing deal with Abbott to develop Alzheimer's blood test - Reuters
Abbott (ABT) Partners with ALZpath for Innovative Alzheimer's Di - GuruFocus
Dividend Stocks That Could Hold Up Better If Rates Stay Higher For Longer - simplywall.st
ALZpath licenses Alzheimer’s antibody to Abbott for diagnostic test - Investing.com
ALZpath licenses Alzheimer’s antibody to Abbott for diagnostic test By Investing.com - Investing.com Canada
How Are Emerging Markets Supporting Abbott's EPD Momentum? - Yahoo Finance
Abbott teams with ALZpath on blood test for Alzheimer's disease - Stock Titan
Abbott Laboratories midweek operations focus, NYSE healthcare stock steady on medical devices and di - Ad-hoc-news.de
Whistleblower alleges Abbott bribed Hawaiʻi provider - Medical Buyer
Abbott Laboratories (ABT) Stock Up 3.1% and Still Undervalued -- GF Score: 80/100 - GuruFocus
Missouri appeals court won't send Abbott's appeal of $495 million preterm baby formula verdict to higher court - Reuters
Abbott Laboratories stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Abbott (ABT) Launches New Diabetes Management Systems in Europe - GuruFocus
Abbott Laboratories (NYSE:ABT): Is Market Too Harsh? - Kalkine Media
Abbott Laboratories Employees Credit Union Data Breach Settlement - Claim Depot
Ultrahuman teams up with Abbott Lingo to fix isolated glucose tracking - Wareable
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Abbott Laboratories (ABT) Stock After 33% One-Year Slide Is The Market Overreacting - simplywall.st
Buy, Sell Or Hold: SBI, Suzlon, Pace Digitek, Zee Entertainment, Urban Company, Abbott Labs — Ask Profit - NDTV Profit
Abbott (ABT) Launches Similac Campaign To Ease Social Media Pressure On Young Parents - Yahoo Finance
Whistleblower: Abbott Laboratories and Hawaiian provider colluded to use more medical devices - HealthExec
ABT Reiterates by Piper Sandler -- Price Target Maintained at $1 - GuruFocus
Similac survey: 80% of young parents feel pressure to be perfect online - Stock Titan
Piper Sandler reiterates Abbott Labs stock rating on growth outlook By Investing.com - Investing.com Canada
Piper Sandler reiterates Abbott Labs stock rating on growth outlook - Investing.com
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.25%
자본화:
|
볼륨(24시간):